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ODDDCNS glia and neurons express connexins, the proteins that form gap junctions in vertebrates. We review the
connexins expressed by oligodendrocytes and astrocytes, and discuss their proposed physiologic roles. Of the
21 members of the human connexin family, mutations in three are associated with signiﬁcant central nervous
system manifestations. For each, we review the phenotype and discuss possible mechanisms of disease.
Mutations in GJB1, the gene for connexin 32 (Cx32) cause the second most common form of Charcot–Marie–
Tooth disease (CMT1X). Though the only consistent phenotype in CMT1X patients is a peripheral
demyelinating neuropathy, CNS signs and symptoms have been found in some patients. Recessive
mutations in GJC2, the gene for Cx47, are one cause of Pelizaeus–Merzbacher-like disease (PMLD), which is
characterized by nystagmus within the ﬁrst 6 months of life, cerebellar ataxia by 4 years, and spasticity by
6 years of age. MRI imaging shows abnormal myelination. A different recessive GJC2mutation causes a form of
hereditary spastic paraparesis, which is amilder phenotype than PMLD. Dominantmutations in GJA1, the gene
for Cx43, cause oculodentodigital dysplasia (ODDD), a pleitropic disorder characterized by oculo-facial
abnormalities including micropthalmia, microcornia and hypoplastic nares, syndactyly of the fourth to ﬁfth
ﬁngers and dental abnormalities. Neurologic manifestations, including spasticity and gait difﬁculties, are often
but not universally seen. Recessive GJA1 mutations cause Hallermann–Streiff syndrome, a disorder showing
substantial overlap with ODDD. This article is part of a Special Issue entitled: The Communicating junctions,
composition, structure and functions.ommunicating junctions, composition, structure and fun
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CNS glia and neurons express connexins, the proteins that form gap
junctions (GJs) in vertebrates. (See Fig. 1 for nomenclature of gap
junction channels and hemichannels.) To date 20 members of the
connexin family have been identiﬁed in mice and 21 have been
demonstrated in humans. (Reviewed by Rackauskas et al. [1].)
Mutations in at least 10 of these connexin genes cause human disease
[2], including three connexins with signiﬁcant CNS manifestations;
these are the focus of this review. Here we emphasize the clinical
phenotypes and current understanding of the pathogenesis of these
genetic diseases, which will require a brief overview of connexin
expression within CNS glial cells, reviewed in more detail elsewhere
[3,4].Cell 2
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Fig. 1. Gap junction nomenclature A. Connexins are integral membrane proteins with
four transmembrane domains and intracellular N and C termini. B. Each connexon or
hemichannel is composed of six subunits called connexins. C. Cell–cell channels are
formed by docking of two apposed connexons from apposed cells. D. If all six subunits
are identical the connexon is termed homomeric. In cells expressing more than one2. Connexins expressed by astrocytes and oligodendrocytes
2.1. Distribution and coupling
Astrocytes (As)2 express Cx30 and Cx43, which can form
homotypic (Cx43/Cx43 and Cx30/Cx30) but not heterotypic
(Cx43/Cx30) GJs in amodel system of transfected cells [5]. Anatomical
approaches also provide evidence that A/A GJs are composed of
Cx43/Cx43 and Cx30/Cx30 homotypic channels [6–9]. Cx43-positive
GJ plaques are found in both gray and white matter, whereas Cx30-
positive GJ plaques are more prominent in gray matter. Although
there are contradictory data [10], some astrocytes may also express
Cx26 [7,9,11,12], which can also form homotypic as well as Cx26/Cx30
heterotypic channels. Inmice, the deletion of the genes encoding Cx43
(Gja1) and Cx30 (Gjb6) results in the complete loss of A/A coupling
[13]. Mutations in GJB2 (encoding Cx26) and GJB6 (encoding Cx30)
are not associated with CNS abnormalities in humans or mice.
Oligodendrocytes (Os) express Cx29, Cx32, and Cx47 [9,14–17].
Cx29 is localized to the adaxonal membrane (apposing the axonal
membrane) of CNS myelin sheaths, but does not form GJs [11,17–19].
In transfected cells, Cx29 does not form functional channels [20], but
its human ortholog, Cx31.3, may form hemi-channels [21]. In rodents,
Cx47 and Cx32 are found in GJ plaques that are localized on the cell
bodies of oligodendrocytes [17], and Cx32 is also localized within the
myelin sheaths themselves [15], although not as distinctly localized
as in Schwann cell myelin sheaths [22]. Though O/O coupling was
not seen in a number of brain regions by conventional electron
microscopy (EM) or freeze replica immune labeling (FRIL) [8,23], two
groups have recently reported the functional O/O coupling in the
mouse corpus callosum [24,25]. The O/O coupling is mediated by
Cx32/Cx32 and Cx47/Cx47 homotypic channels, as it is present in
mice lacking Cx32 or Cx47, but is lost in mice that lack both Cx32 and
CxCx47. Furthermore, EM demonstrated that oligodendrocytes are
directly joined by GJs [24].
Electron microscopic studies in the 1980s provided anatomical
evidence that oligodendrocytes were GJ coupled to astrocytes, but not
to themselves [26,27]. Our work in a model system of transfected cells
shows that Cx43/Cx47 and Cx30/Cx32 (but not Cx43/Cx32 or
Cx30/Cx47) form morphologic and functional GJs that have distinct2 Non-standard abbreviations. A—astrocyte O—oligodendrocyte GJ—gap junction
KO—knockout(null) dKO—double knockout WMC: white matter changes.electrophysiological properties [5], but using a different approach,
another group [28] showed that Cx30 and Cx47 can form functional
channels. Anatomical studies in the CNS [7,9,13,15] make a strong
case that A/O GJs consist predominantly of Cx43/Cx47 and Cx30/Cx32
heterotypic channels (a role for Cx26/Cx32 channels remains to be
excluded or proved). In the cerebral cortex, A/O coupling is lost in
Cx47- (Gjc2), but not in Cx32- (Gjb1) null mice, indicating that
Cx43/Cx47 channels (and not Cx30/Cx32 channels) are required for
A/O coupling, at least in this region [24].
2.2. Roles of glial connexins in CNS glia
2.2.1. Lessons from mice with targeted ablation of one or more connexins
The roles of connexins in CNS glia are now beginning to be
explicated. Mice with targeted deletion of oligodendrocyte connexins
Cx29, Cx32, and/or Cx47 and mice with targeted deletion of astrocyte
connexins Cx30 and/or Cx43 have been examined. A thorough
understanding of the phenotypes of these mice is critical to
understanding of the pathogenesis of disorders associated with
mutations in these connexins. Cx32- (Gjb1-) null mice develop atype of connexin, different connexins may aggregate to form heteromeric connexons.
E. Many members of the connexin family can form functional GJs by associating with a
like connexon (a homotypic junction) or a different one (a heterotypic junction).
2032 C.K. Abrams, S.S. Scherer / Biochimica et Biophysica Acta 1818 (2012) 2030–2047demyelinating peripheral neuropathy after 3 months of age [29,30],
but only subtle changes in CNS myelin thickness [31,32] are seen. To
date, no behavioral abnormalities have been described in this mouse.
Similarly, Cx47- (Gjc2-) null mice show no behavioral abnormalities
and only minimal and regionally limited abnormalities in some
myelin sheaths [14,16]. In contrast, mice lacking both Cx32 and Cx47
present with abnormal movements and seizures as well as striking
CNS pathology including demyelinated and remyelinated axons, and
enlarged extracellular space that separates the axon from its myelin
sheath (See Fig. 2); these ﬁndings lead to the speculation that this
vacuolization might be due to failure of spatial buffering of potassium
with increased periaxonal accumulation in the double KOmouse [16].
This idea is supported by data showing that mice with targeted
deletion of Kir4.1 [33], an inwardly rectifying K+ channel [34,35], also
develop vacuoles [33], and that the null allele of Kir4.1 genetically
interacts with the null alleles of Cx32 and Cx47 [36].
Though the original theory of spatial buffering of potassium
referred only to the role of astrocytes (and presumably A/A coupling)
in regulating the levels of extracellular potassium [37], work by
Menichella et al. [36] supports the hypothesis that oligodendrocyte
Cx32 and Cx47 are involved in spatial buffering of K+ during neuronal
activity. Optic nerve vacuoles are reduced by suppressing activity of
retinal ganglion cell (intraocular injection of tetrodotoxin); converse-
ly, enhanced activity (intraocular injection of cholera toxin) causes
increased vacuolization.
Although Cx29 (the mouse ortholog of human Cx31.3) is widely
expressed in the CNS during development [38] and in the small
myelinated ﬁbers of mature brain and spinal cord [11,17–19], no CNS
physiological or pathological phenotype is seen in mice with targetedFig. 2. Ultrastructural ﬁndings in the CNS myelin of mice lacking expression of Cx32
and Cx47. All are electron micrographs of the ventral funiculus from P31 mice. A. An
axon (a) is surrounded by a periaxonal cytoplasmic collar thin myelin sheath (arrow).
B. A demyelinated axon. Note that neuroﬁlament packing is tighter than in A. C. An axon
still partially surrounded by the adaxonal membrane (arrowheads), but separated from
its myelin sheath (arrow) by- extracellular space (asterisks). D. An apoptotic
oligodendrocyte nucleus (n). Scale bar, 1 μm.
From Menichella et al. 2003, [16] used with permission of Society for Neuroscience.ablation of Cx29 [39] though peripheral auditory pathways are
affected [9,40]. Whether mutations in GJE2 [41], the gene encoding
Cx31.3, cause hearing loss in humans needs to be conﬁrmed.
Studies of mice with targeted deletion of Cx30 and Cx43, the two
astrocyte connexins have also been revealing. Both Wallraff et al. [13]
and Theis et al. [42] studied mice with astrocyte speciﬁc deletion of
Cx43 alone and found approximately a 50% reduction in A/A coupling.
Mice expressing no astrocyte Cx43 and no Cx30 in any cell (Cx43Astro–
Cx30 dKO) showed no A/A coupling and reduced hippocampal K+
buffering [13] as well as loss of metabolic coupling through astroglial
networks [43]. Unlike the Cx32–Cx47 dKO mice [16], these mice had
no gross behavioral abnormalities (but see below in this section) or
reduced life expectancy [13,44]. These ﬁndings indicate that loss of
O/O coupling has greater impact on CNS function than does loss of A/A
coupling, since in both cases it is likely that all A/O coupling is
eliminated. Theis et al. [42] found increased locomotor activity and an
increase in the velocity of spreading depression in the astrocyte
speciﬁc Cx43KO mouse. The authors suggest that astrocyte GJ
communication may attenuate spreading depression by reducing
extracellular K+ or glutamate. This hypothesis is supported by the
recent work of Pannasch and colleagues [45] showing that astroglial
gap junction coupling is required for clearance of extracellular
glutamate generated by synaptic activity. Lutz et al. [44] found
prominent white matter abnormalities in Cx43Astro–Cx30 dKO mice
that are similar to those noted in Cx32–Cx47 dKO and Kir4.1 KO mice
(See Fig. 3). Gray matter involvement was restricted to astrocyte
swelling in the CA1 region of the hippocampus. Behavioral testing
showed decreased performance on testing of hippocampal spatial
learning. Detailed behavioral analyses of this mouse as well as the
Cx43Astro KO and Cx30 KO mice have been performed and are
summarized in Table 1.
2.2.2. Physiologic roles of glial connexins
The best recognized role of connexins is to formGJs, which provide
a pathway for electrical and/or metabolic coupling between cells [46].
In glial cells, GJ coupling is likely to underlie the formation of a glial
syncitium [47]. Because glial gap junction coupling is a dynamic
process regulated by intra- or extracellular signals (reviewed in
Giaume et al. [48]) it has been suggested that coupled glia should be
referred to as a network rather than a syncitium. One function of such
a syncitium/network is propagation of Ca2+ waves (see [49] for
more detail). As noted above (Section 2.1) Cx32 may also provide
reﬂexive coupling between adjacent loops of non-compact myelin
[50]. In the last decade, however, other roles are being described for
connexins. GJs may be part of a larger complex that contains other
junctional elements. Several connexins, including Cx43 and Cx47,
have a PDZ-binding domain on their C-terminus, and bind to ZO-1,
one of the deﬁning members of PDZ family [19,51–56] In Gjc2-null
mice the association between Cx47 and ZO-1, ZO-1-associated nucleic
acid binding proteins (ZONAB), and multi-PDZ domain protein 1
(MUPP1) is lost [57]. Instead of being co-localized with Cx47, ZONAB,
a Y-box transcription factor, has increased cytoplasmic and nuclear
localization. This redistribution could affect oligodendrocytes, as
ZONAB can repress ErbB2 [58], a tyrosine kinase receptor implicated
in oligodendrocyte development, differentiation and survival [59–61].
ZONAB also regulates a number of cell cycle regulatory genes [62,63].
These ﬁndings suggest that the appropriate localization of Cx47 in the
oligodendrocyte may be important for stabilization/organization of
the oligodendrocyte membrane junctional complex, as well as for
appropriate regulation of gene expression and control of the cell cycle.
Other data suggest that connexins may have roles in regulation of cell
growth [64–68] and resistance to both apoptotic and necrotic cell
death [69] that are independent of formation of functional GJ
channels. Recent work from one of our laboratories has shown that
Schwann cell proliferation is regulated by Cx32 in a GJ-independent
manner [68].
Fig. 3. Pathologic ﬁndings in the CNSmyelin of mice lacking expression of Cx30 globally and Cx43 in astrocytes (Cx30 Cx43astro dKO). A–C. Toluidine blue stained 1 μmepoxy sections
of the dorsal cuneate of the lumbar spinal cord of non-Cre (Cx43ﬂ/ﬂ Cx30−/− (A) and Cx30 Cx43astro dKO (B, C) mice. D, Electron micrograph showing enlarged oligodendrocyte
cytoplasm interpolating between an apparently normal axon and its myelin sheath. Inset depicts ectopic expression of myelin in one of several locations within the oligodendrocyte
cytoplasm. E. Myelin whorls, likely representing Wallerian axonal degeneration. F and G. Edema and splitting of myelin sheaths. Scale bar: (A, B) 100 μm; (C) 10 μm. Magniﬁcation:
(D) 4000×, inset: 15,000×; (E) 9000×; (F) 8000×; (G) 13,000×, inset: 4000×.
From Lutz et al. [44] used with permission of Society for Neuroscience.
2033C.K. Abrams, S.S. Scherer / Biochimica et Biophysica Acta 1818 (2012) 2030–2047Connexin hexamers can form functional membrane hemichannels
that maymediate a variety of cellular processes, including ATP release
and signaling [70–72], glutamate release [72,73], glutathione release
[74], and responses to spinal cord injury [75]. Astrocyte Cx43Table 1
Behavioral phenotypes of astrocyte connexin KO mice. NR not reported.
Phenotype Cx43Astro KO vs. WT [199] Cx30 KO vs. WT [200]
Test
Rotarod Reduced time on rod day 1. Trend toward reduced
Balance beam NR NR
Spatial memory NR Reduced contact with
Visual memory NR NR
Open ﬁeld Increased horizontal activity. Reduced time in cente
Reduced rearings.
Graded anxiety No difference.
Water maze Steeper learning curve. NR
Plus maze Slight increased entry into closed arms. NR
a Not analyzed day by day.hemichannels are reportedly modulated in a number of pathogenic
states including metabolic inhibition [76] and brain abscesses [77],
and may be upregulated by proinﬂammatory cytokines secreted from
microglia [78]. Cannabinoids may antagonize the effect ofCx43Astro-Cx30 vs. WT [44]
time on rod. Reduced time on rod.a
More falls, longer crossing time.
displaced object. Reduced contact with displaced object.
No difference.
r and increased time in corners of ﬁeld. NR
NR
NR
NR
2034 C.K. Abrams, S.S. Scherer / Biochimica et Biophysica Acta 1818 (2012) 2030–2047proinﬂammatory cytokines [79]; this may be neuroprotective [80].
However, recent work suggests that at least in cultured astrocytes,
pannexin 1 and not Cx43 is responsible for the membrane conduc-
tances and permeabilities ascribed to astrocytic hemichannels
[81]. Hemichannel activities ascribed to Cx30 [82,83], Cx47 [84],
Cx32 [85–87], and Cx31.3 [21] have all been identiﬁed in cultured cells,
but their importance in glial physiology remains to be determined.3. Disease manifestations of GJB1 mutations
3.1. CMT1X clinical phenotypes MIM ID #302800
Charcot–Marie–Tooth disease (CMT) is the eponym for large
number of inherited disorders affecting predominantly or exclusively
the peripheral nerves. Symptoms are those of peripheral neuropathy
and include weakness and sensory loss of the distal more than
proximal extremities. The most common X-linked form of CMT,
termed CMT1X, arises in patients with mutations in GJB1, the gene
that encodes Cx32, which is expressed in both Schwann cells and
oligodendrocytes and a number of other cell types [88]. In spite of its
widespread expression, a demyelinating peripheral neuropathy is theFig. 4. Mutations in Cx32 associated with CNS manifestationsonly consistent phenotype of the more than 400 mutations that have
been reported to date. The CNS signs and symptoms that have been
found in some patients with CMT1X are described below, along with
their potential mechanisms.
CNS manifestations of CMT1X can be divided into three groups:
1) subclinical abnormalities of visual evoked responses (VERs) and
auditory evoked responses (BAERs); 2) overt, generally mild ﬁxed
abnormalities on neurological examination and/or CNS imaging and
whichmay ormay not be accompanied by clinical manifestations; and
3) severe transient CNS dysfunction accompanied by white matter
changes (WMC) on MRI. See Fig. 4 for a schematic of mutations
associated with these abnormalities. Although hearing loss has been
associated with several mutations including R142Q [89], E186K [90]
T191FS, T55R [91] and V38A [92] it remains to be shown that this is
truly a phenotypic manifestation of these mutations.3.1.1. CMT1X subclinical manifestations
Nicholson and colleagues [93,94] were the ﬁrst to report
prolongation of BAERs in many but not all patients with CMT1X. A
number of other investigators have conﬁrmed and extended this
ﬁnding, showing conduction slowing of VERs [89,91,95–101] as well. Topology is as depicted in Yeager and Nicholson [198].
2035C.K. Abrams, S.S. Scherer / Biochimica et Biophysica Acta 1818 (2012) 2030–2047as motor [102] and sensory evoked potentials. (SEPs) [103] In a
particularly noteworthy study Zambelis et al. [104] measured evoked
potentials (blink responses, SEPs, and transcranial magnetic central
motor conduction time) in seven affected family members (3 female
and 4 male) carrying the Y154STOP mutation. All male and female
patients had abnormalities in at least one of these tests; however,
males tended to have abnormalities in multiple tests [104]. Nicholson
and colleagues [94] reported that several mutations in CMT1X
patients they evaluated were not associated with abnormalities of
BAERs, including L239I [94] and Y151K, V181M, R183C (G Nicholson,
personal communication). Interestingly, patients with complete
absence of the coding sequence of Cx32 [90,105] have no abnormal-
ities of VERs or BAERs, suggesting that these CNS ﬁndings are due to
gain of function.3.1.2. Subtle clinical manifestations
A few mutations are associated with mild, static clinical abnor-
malities that are signs of CNS dysfunction. For example, a number of
patients have been reportedwith extensor plantar responses [91,106–
108]. In addition, ﬁxed spasticity, hyperreﬂexia, dysarthria and ataxia
have also been reported [102,107,109,110]. A number of studies have
reportedMRI imaging abnormalities in CMT1X patients. Inmost cases,
these imaging abnormalities are accompanied by clinical ﬁndings
[91,102,108,109], while in at least two cases no mention is made of
accompanying clinical signs or symptoms [111,112] Interestingly, two
reports [102,109] describe diffuse involvement of the corticospinal/
corticobulbar tracts, suggesting that this tract may represent a
selectively vulnerable region; the predominance of ﬁndings indicative
of corticospinal dysfunction in patients with ﬁxed abnormalities, andT1 T2
Onset
1 month
2 months
Fig. 5. MRI imaging of a CMT1X patient with an acute ﬂorid CNS presentation. T1-weight
magnetic resonance imaging (DWI) images during onset of an acute CNS syndrome and 1
images at onset) and posterior limb of the internal capsule abnormalities at all three time p
Modiﬁed from Paulson et al. (2003) [113], used with permission of Wiley-Davis.the predominance of corticospinal ﬁndings in patients with ﬂorid
acute syndromes (see below) also suggest this possibility. A few
additional reports describe patients with scattered white matter
lesions [91,108,111].
3.1.3. Florid syndromes
A growing number of CMT1X patients who experienced transient
neurological dysfunction accompanied by transient white matter
abnormalities on MRI have been reported (see Fig. 5). Findings
typically include motor weakness and dysarthria [97,113–119]. In
addition, ataxia [113], respiratory distress [114], dysphagia [115,117]
and disorientation [119] have also been described. The duration of
symptoms varies, but they usually resolve between a few hours and a
few weeks. However, the MRI changes typically lag, taking months to
return to baseline [97,113,115,119,120]. Some of these episodes
appear to occur without provocation [97,116], but many are
associated with stressors such as hyperventilation or exertion
[97,115,120] re-acclimitization after return from high altitude above
8000 ft [113], fever [114,119], or minor infections [115,117].
3.2. Pathophysiology of CNS phenotypes in CMT1X patients
The absence of clinical or even subclinical abnormalities of VERs or
BAERs in patients with complete absence of the coding sequence of
Cx32 [90,105], and the absence of overt CNS manifestations in most
patients with CMT1X and in the Cx32 KO mouse [29–31] suggest that
Cx32 is not critical for CNS functioning [30]. Thus, the subclinical and
overt CNS manifestations of CMT1X are unlikely to arise through
simple loss of function of Cx32, suggesting that Cx32 mutants cause aFLAIR DWI
ed, T2-weighted, ﬂuid-attenuated inversion recovery (FLAIR), and diffusion-weighted
and 2 months later show splenium of corpus callosum (arrow in the T2, FLAIR and DWI
oints; signal intensities have almost returned to normal after 2 months.
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known. One possibility is that Cx32 mutants interact heteromerically
with Cx47 expressed in the same cells, thereby reducing the activity of
Cx47. The additive effect would be greater than the loss of Cx32
activity alone, and sufﬁcient to cause the subclinical symptoms or to
predispose patients to the acute, ﬂorid syndromes described above,
just as mice lacking expression of both Cx32 and Cx47 have a much
more severe phenotype than mice lacking either connexin alone, as
described in Section 2.2.1.
We and others have expressed some of these CMT1XCNS mutants
in heterologous cells, and examined their ability to form functional GJs
[86,107,121–128]. Because many mutants associated with CNS
phenotypes are localized intracellularly and do not form GJ plaques,
it is tempting to speculate that abnormal subcellular localization
predicts abnormal interaction with Cx47 and thereby predicts CNS
manifestations [124]. (For example, among mutant showing abnor-Fig. 6. Mutations in Cx47 associated with human disease. Tmal subcellular localization [107,124,128,129], R142W, R164W, and
R164Q are associated with acute attacks as described in Section 3.1.3
and A39V and L143P are associated with clinical and/or MRI ﬁndings
as described in Section 3.1.2.) However, other mutants associated
with these same CNS phenotypes can formGJs [124,127–129] (V139M
is associated with acute attacks; V35M, P158A, N205S, R220x, show
evoked potential abnormalities but no overt phenotype; and M93V
and R183H are associated with clinical and/or MRI ﬁndings). Further,
some mutants with abnormal subcellular localization have no clinical
or subclinical CNS phenotype [94].
As noted in Section 3.1.3, the acute, reversible encephalopathy that
occurs in CMT1X has often been associated with stressors such as an
acute febrile illness or return to lower altitudes after adapting to
higher altitudes. The precise physiological trigger(s) have not been
identiﬁed, but pro-inﬂammatory cytokines (for systemic illnesses)
and decreases in pH (associated with going from high to low altitude)opology is as depicted in Yeager and Nicholson [198].
Fig. 7. MRI imaging of patients with PMLD1. Axial T2-weighted magnetic resonance
images of the brain at the level of the basal ganglia. A. Patient with PMLD at 6 years of
age. B. Patient with PMD at 7 years of age. The patients in panels A and B show nearly
identical patterns consistent with hypomyelination of central white matter, as
indicated by diffusely enhanced signal intensity. C. Low signal of normal myelination
in an unaffected child.
From Uhlenberg et al. [134] used with permission of Elsevier.
Rb αCx47 merge
CX47WT
I33M
P87S
Fig. 9. Immunostaining for the I33M and P87S mutants. The SPG44 associated I33M
mutant forms GJ plaques while the PMLD1 associated P87S mutant does not. These are
confocal images of bulk-selected HeLa cells that express WT Cx47 or the indicated
mutants, immunostained with a rabbit antiserum against human Cx47 (red) and a
mouse monoclonal antibody against pan-cadherin (green), and counterstained with
DAPI. The pan-cadherin staining at cell borders interdigitates with the cell surface
staining of Cx47 in cells that expressWT Cx47 (arrowheads) or I33M (arrowheads), but
surrounds the staining of cells expressing the mutant P87S, which is localized in the
endoplasmic reticulum. Scale bar: 10 μm.
From Orthmann-Murphy et al. [140] used with permission of Oxford University Press.
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with these transient CNS events have trans-dominant-negative effects
on Cx47, thereby reducing O/O and/or O/A coupling. Pro-inﬂamma-
tory factors such as tumor necrosis factor-α may directly inhibit glial
GJs [130], exacerbating already tenuous GJ coupling and leading to
clinical manifestations. Returning to lower altitudes after adapting to
higher altitudes decreases the pH of the cerebrospinal ﬂuid; (CSF)
[131] lower pH reduces GJ coupling [132]. At 13 h after return to
normoxia only a small drop in CSF pH is seen (0.03 pH units) [131];
however longer time points were not studied and the full extent of
this dropmay be greater. In any case a small pH drop could conceivably
affect already tenuous O/A and O/O coupling, since reducing the pH in
patch electrodes from 7.4 to 7.2 has dramatic effects on Lucifer Yellow
transfer from oligodendrocytes [24].
4. Disease manifestations of GJC2 mutations
4.1. Pelizaeus–Merzbacher-like disease 1 (PMLD1) MIM ID #608804
Pelizaeus–Merzbacher disease (PMD) is an X-linked disorder
caused by mutations in PLP1, the gene for proteolipoprotein (PLP),
the major protein of CNS myelin [133]. Pelizaeus–Merzbacher-like
disease is a group of diseases in patients with a PMD phenotype but
lacking PLP1 mutations. Patients typically develop nystagmus within
the ﬁrst 6 months of life, cerebellar ataxia by 4 years, and spasticity by
6 years of age [134–137]. In 2004 Uhlenberg and colleagues reported
that mutations in GJC2, the gene encoding Cx47, were found in some
PMLD patients [134]. GJC2 mutations are found in only ~8% of PMLD
patients [138]. GJC2 associated PMLD is termed PMLD1 or HLD2
(hereditary leukodystrophy type 2.) To date, 23 different CNS disease
associated recessive mutations in the coding region of the gene forA B
Fig. 8. MRI imaging of a patient with SPG44. A. Sagittal T1-weighted imaging shows diffus
hyperintensity in the region of the corticospinal/corticobulbar tracts at the level of the pons (B
diffuse hyperintensity in the subcortical, lobar and periventricular white matter (C and D),
Modiﬁed from Orthmann-Murphy et al. [140] used with permission of Oxford University PCx47 have been identiﬁed [134–139]. All patients with PMLD have
extensive white matter disease consistent with abnormal myelination
on MRI; relative sparing of the corticospinal tracts has been reportedC D
e thinning of the corpus callosum. B–D. Axial T2-weighted imaging shows symmetric
, arrows), and the posterior limb of internal capsule (C, arrowhead). In addition, there is
and enlarged ventricles (C).
ress.
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137] MRI spectroscopy studies in two patients showed normal or near
normal choline, N-acetyl aspartate and creatine levels [137] (normal
N-acetyl aspartate levels indicate lack of signiﬁcant axonal damage).
Fig. 6 shows a schematic of Cx47 mutants associated with human
disease.
4.2. Hereditary spastic paresis (SPG44) MIM ID #613206
Orthmann-Murphy et al. [140] described a large family with three
affected members carrying a homozygous I33M mutation of GJC2
(Fig. 6). One male patient (age 38) developed moderate walking
difﬁculties, leg stiffness and dysarthria around age 31. His brother
(age 36) had minimal motor difﬁculties since infancy but began toFig. 10. Mutations in Cx43 associated with human disease.show progressive worsening of his gait and speech after age 20; he
walks with a cane. A female cousin (age 55) was always considered
dull, had difﬁculty walking and dysarthria in her teens and has been
wheelchair bound since age 30; more recently she has developed
urinary incontinence followed by retention. All three patients had
spasticity, hyperreﬂexia, and intention tremor on exam and none had
nystagmus. All heterozygous individuals in the family were normal. In
summary, although only identiﬁed in one family thus far, SPG44 is a
clinically much milder disease than is PMLD1 with correspondingly
milder changes on the cerebral MRI (Fig. 8). Notably, some PLP1
mutations can also present with a paraperesis phenotype (SPG2)
[141]. Thus, SPG44 and SPG2 are causes of hereditary spastic
paraparesis associated with mutations in genes that are expressed
primarily by oligodendrocytes, and both can also cause a more severeTopology is as depicted in Yeager and Nicholson [198].
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because the spastic paraplegia phenotype is thought to represent a
length dependent axonopathy, and suggests that mutant forms of
Cx47 may directly interfere with important interactions between
an oligodendrocyte and their associated axons. (The central motor
axons to the lumbar segments are the longest central axons in the
body and therefore, the most susceptible to length-dependent
pathology.)4.3. Hereditary lymphedema 1C MIM ID #613480
A recent report [142] identiﬁed six dominant mutations in Cx47
associated with hereditary lymphedema (Fig. 6). However, no
neurological histories, examinations, or imaging were provided.4.4. Pathogenesis of Cx47 associated diseases
One explanation, consistent with the recessive inheritance pattern
and relatively uniform phenotype, is that PMLD1 arises due to loss of
channel function of Cx47 in oligodendrocytes. The recent ﬁnding by
Osaka and colleagues [143], that a mutation in the SOX10 binding site
in the GJC2 promoter causes a mild PMLD phenotype [144],
intermediate between that of PMLD1 and SPG44, lends support to
the idea that in humans, loss of function of Cx47 is pathogenic and
that degree of loss of function may predict severity of phenotype.
However, these ﬁndings do not rule out gain of function as a
contributor to the more severe phenotypes. Data from our laborato-
ries [140] suggest that PMLD1 mutations lead to complete loss of gap
junctional coupling, while the SPG44 mutation causes radical
alterations in gating, predicted to essentially eliminate Cx47-mediat-
ed coupling; thus, it is unlikely that the milder phenotype of SPG44
results from retention of a small degree of Cx47 mediated coupling.
The work of Diekmannn et al. [84,85] suggests that loss of
hemichannel function is a feature of some Cx47 mutants, and may
represent an additional component of loss of function of some or all of
the Cx47 mutants. The ﬁnding that mice with targeted ablation of the
gene for Cx47 show minimal [14] CNS pathology or phenotypic
abnormalities is also inconsistent with a pure loss-of-function model
for PMLD1; however it could simply reﬂect that mouse oligodendro-
cytes are less dependent on expression of Cx47 for normal function
than are human oligodendrocytes. This notion is supported by the
recent demonstration [145] that mice with targeted insertion of the
Cx47M282T mutation (corresponding to the human PMLD1 causing
Cx47M283T mutation) have a very mild phenotype compared to that
seen in humans.
A second possibility is that both the PMLD1 and SPG44 mutants
lead to a loss of channel function, but that the PMLD1 mutations lead
to the loss of an additional non-channel based function.We found that
each of three missense Cx47 mutants associated with PMLD1
accumulates in the endoplasmic reticulum [146], while the SPG44
mutant I33M forms GJ plaques that are indistinguishable from WT
Cx47 [140] (see Fig. 9). Our data [146] suggest that PMLD1 mutants
may not fold and/or assemble properly. PLP mutants that cause the
most severe phenotypes also accumulate in the ER, and activate the
unfolded protein response (UPR) [147–149], a group of cellular
signaling pathways that can lead to apoptosis [150,151]. The three
missense Cx47mutants associatedwith PMLD1 did not activate CHOP,
a downstream effector of the UPR [146] that is activated in PMD [148].
However, a more complete evaluation of the UPR pathway, particu-
larly in oligodendrocytes, is needed before rejecting the hypothesis
that the UPR is not involved in PMLD1. Finally, as discussed in
Section 2.2, the loss of junctional Cx47 leads to mislocalization of
ZONAB to the nucleus, which could alter gene expression, and thus
contribute to the greater severity of the PMLD1 phenotype.5. Disease manifestations of GJA1 mutations
5.1. Oculodentodigital dysplasia (ODDD) MIM ID #164200
ODDD is a pleitropic autosomal dominant disorder seen in
patients with mutations in GJA1, the gene for Cx43. [152]; these
are depicted in Fig. 10. Although a number of patients with this
disorder had already been described [153], the deﬁnitive delineation
of ODDD dates to the German language publication of “The
Microphthalmos Syndrome” by Meyer-Schwickerath in 1957 [154],
in which the term ‘dysplasia oculo-dento-digitalis’ was introduced.
In 1963, Gorlin et al. [155] reviewed the known cases and deﬁned the
core features of syndrome of ODDD as oculo-facial abnormalities
including micropthalmia, microcornia and hypoplastic nares, syn-
dactyly of the fourth to ﬁfth ﬁngers and dental abnormalities such as
hypoplastic enamel and microdontia. See Supplementary Tables 3 to
5 in Paznekas et al. [156] for detailed and comprehensive
information on the general phenotypes of patients carrying speciﬁc
mutations in Cx43. Neurologic manifestations are often but not
universally seen, and may not become evident until the second or
third decade. The most common are gait difﬁculties [153,157–169],
due to either spasticity or ataxia, and urinary incontinence [166–
169]; these typically present by the second decade. A wider range of
neurologic symptoms have been reported [153], including cognitive
deﬁciencies [157,170], deafness [171,172], disorders of extraocular
motility [161,168,171], generalized muscle weakness, and seizures
[152]. MRI abnormalities include hypointensity of the deep gray
matter, which may reﬂect iron deposition, and changes in the
occipital and periventricular white matter [153,164,165]. (See
Table 2 for further references to neuroimaging.) In some cases
where CT imaging was used, the basal ganglia were calciﬁed
[161,173]. Abnormalities in CNS imaging accompany overt CNS
ﬁndings, but may also be seen in patients without neurological issues
[170], raising the possibility that many mutations reported as
showing no neurologic phenotype may still cause subclinical CNS
changes. Along this line, an MRI imaging study [165] of a
neurologically symptomatic mother and neurologically normal
daughter with ODDD both showed identical changes in the white
matter. The clinical and subclinical neurological ﬁndings in patients
with ODDD are summarized in Table 2.5.2. Hallermann–Streiff syndrome (HSS); MIM ID 234100
HSS is an autosomal recessive or sporadic syndrome that is at
least sometimes associated with mutations in GJA1. The clinical
phenotype shows substantial overlap with the ODDD, characterized
by brachycephaly with frontal bossing, micrognathia, a beaked nose,
microphthalmia, cataracts, dental anomalies, hypotrichosis, skin
atrophy, and short stature [174–176] Mental retardation is present
in some patients [177]. A homozygous R76Hmutation was noted in a
boy with HSS [178,179]; his parents were heterozygous carriers of
the mutation and were clinically normal. In another case of HSS,
Pizzuti et al. [179] found no GJA1mutation in the open reading frame,
but did not rule out mutations in the promoter or untranslated
regions of GJA1. Reports of homozygous [180,181] or compound
heterozygous mutations [173] causing ODDD further demonstrate
the overlap between HSS and ODDD. A few case reports of HSS had
abnormal neuroimaging, but were not studied for GJA1 mutations.
Sigrici and colleagues [182] describe a four year old boy with the HSS
phenotype, nystagmus, spasticity, optic atrophy and complete
agenesis of the corpus callosum. Decreased size of the cerebellum
and medulla size on MRI has also been reported [183]. These reports
should be viewed cautiously since, as noted above, at least one
patient with a “full blown” HSS phenotype had no mutations in the
GJA1 coding region [179].
Table 2
Features of mutations in Cx43 associated with ODDD.
Mutation Functional assay (transfected cell lines unless
noted)
Localization in mammalian cells (transfected
cell lines unless noted)
Neurologic phenotype References
Explicit statement of no neurologic manifestations
S5C 9 YO “no mental retardation or brain
wave abnormality.” [201]
[201]
L11P 13 YO, de novo mutation.
No neuro. ﬁndings. [202]
[202]
S18P GJ-like plaques. (S. Scherer, unpublished) No neuro. ﬁndings. [152] [152] originally described in [203,204];
V41A 11 YO, neuro. exam nl. [205]
Q49K Low homotypic coupling and minimal dominant
negative effect on endogenous Cx43 mediated NRK
cell coupling. [185]
GJ-like plaques. [185] (S. Scherer, unpublished) No neuro. ﬁndings. [152] [152] originally described in [206];
F52dup No junctional homotypic coupling. [189]
No dye transfer by scrape load or hemichannel
activity by dye uptake. [188]
ER staining pattern [189]
Very reduced puncta. [188] Normal localization
(basolateral) in MDCK cells. [186]
Endosomal. (S. Scherer, unpublished)
No neuro. ﬁndings. [152] [152] originally described in [207];
R76H Affected child has homozygous
mutation; parents are heterozygotes;
no neuro. ﬁndings.
[208].
V96E 12 YO with de novo mutation in; no
neuro. ﬁndings.
[157]
Y98C GJ-like plaques. (S. Scherer, unpublished) No neuro. ﬁndings. [152] [152] originally described in [206,209];
H194P Normal hemichannel activity. No neurobiotin
transfer [193]
GJ-like plaques and cytoplasmic. [187] No syndactyly or spastic paraplegia.
[156,210]
[210]
R202H No homotypic coupling. [189] Low coupling and
dominant negative effect on endogenous Cx43
mediated NRK coupling. [185]
GJ-like plaques (S. Scherer, unpublished) No
plaques, some overlap with ER marker. [189]
Few plaques partial intracellular retention. [185]
No neuro. ﬁndings. [152] [152,211,212]
C260fs Decreased endogenous plaques when expressed in
NRK cells; decreased coupling and dominant
negative effect on WT Cx43 in transfected cells
[192]
ER retained [192] Neurologically normal [213] [213]
Y230fs No neuro. or eye problems. [156,214] [214]
A253V Polymorphism [152]
Neurologic manifestations not mentioned
G2V Nothing stated. [215]
L7V Nothing stated. [156]
G22R Nothing stated. [156]
S27P Nothing stated. [211]
I31M Nothing stated. [211]
E48K Nothing stated. [216,217]
Q49dup Nothing stated. [156]
N55D Nothing stated. [156]
Q58H Nothing stated. [156]
P59A Nothing stated. [156]
P59H Nothing stated. [218]
S69Y Nothing stated. [211]
H74L Nothing stated. [156]
V85M Nothing stated. [212]
V96M Nothing stated. [219]
E110D Nothing stated. [220]
I131M Increased hemichannel activity. No neurobiotin
transfer.[187]
GJ-like plaques and cytoplasmic. [187] Nothing stated. [211]
G138D Nothing stated. [212]
G138S Nothing stated. [156,212]
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G143S Increased hemichannel activity. No neurobiotin
transfer. [193]
GJ-like plaques and cytopasmic. [187] Nothing stated. [211]
G143D Nothing stated. [212] [156]
K144E Nothing stated. [156]
V145G Nothing stated. [156]
M147T Sporadic case; nothing stated. [220]
R148Q Nothing stated. [211] originally described in [221]
R148G Nothing stated. [156]
F169del Nothing stated. [220]
P193L Nothing stated. [156]
S201F Nothing stated. [156]
S201Y Nothing stated. [212]
Explicit description of neurologic manifestations
G2fs G2fs+R101x; severe CNS phenotype,
psychomotor regression onset age 10,
seizures; massive calciﬁcations,
hypomyelination, and atrophy on
CT/MRI. [173]
[173]
D3N Decreased coupling in patient ﬁbroblasts. [169] Partial localization in Golgi (but also someWT in
golgi distribution) in patient ﬁbroblasts. [169]
Neurogenic bladder, UMN. [169] [156,212,169]
Y17S No junctional coupling. [189]
No dye transfer by scrape load or hemichannel
activity by dye uptake. [188]
GJ-like plaques. (reduced nos.) [188]
GJ-like plaques. (S. Scherer, unpublished)
“Neuro. deﬁcits were prominent.”
[206] UMN, ur. inc. [156]
[152] originally described in [206,222]
G21R No homotypic junctional coupling. [189,190] No
dye transfer by scrape load or hemichannel activity
by dye uptake. [188] Dominant negative effect on
endogenous 43 in NRK cells [190] and Hela and N2a
cells. [223]
GJ-like plaques. (reduced numbers) [189]
[188,190]
No neuro. symptoms but patient is a 2
YO with a sporadic mutation. [152]
UMN. [156]
[152]
G22E GJ-like plaques. (S. Scherer, unpublished) “Neuro. Symptoms.” [152] [152] originally described in [224]
K23T GJ-like plaques. (S. Scherer, unpublished) “Neuro. Symptoms.” [152] UMN, MRI
WMC, tremor. [156]
[152] originally described in [155]
R33x 2 siblings homozygous for this
mutation; speech delay, UMN, grossly
abnormal gray/white matter
differentiation on head CT. [180]
[180,181]
A40V No homotypic coupling. [189] No dye transfer by
scrape load or hemichannel activity by dye
uptake.[188]
GJ-like plaques. (reduced numbers) [188,189]
GJ-like plaques. (S. Scherer, unpublished)
No neuro. symptoms but patient is a 2
YO with a sporadic mutation. [152]
gait difﬁculty, ur. urgency [156]
[152, 211, 220]
Q49P Ur. inc. [156]
R76S GJ-like plaques. (S. Scherer, unpublished) “Neuological deﬁcits were
prominent” [206] Epilepsy [152] MRI
WMC [156]
[152] originally described in [225]
L90V Coupling very low, single channel conductance
normal. [189] Low junctional conductance and
dominant negative effect on endogenous Cx43
mediated NRK coupling. [185] No dye transfer by
scrape load or hemichannel activity by dye uptake.
[188]
GJ-like plaques. (reduced nos.) [188,189]
Disrupted localization (partial apical) in MDCK
cells. [186]
GJ-like plaques. [185]
GJ-like plaques. (S. Scherer, unpublished)
“Neuro. deﬁcits were prominent”
[206]
Epilepsy. [152]
Ur. inc. and spastic paraplegia (9/9
patients) [156,226]
[152] originally described in [206,226,227]
H95R Ur. inc. and spasticity [166] MRI WMC
[156]
[166]
V96A MRI WMC. [156] originally described in [162]
R101x Compound heterozygote G2fs+
R101x; see G2fs above.
[173]
K102N GJ-like plaques. (S. Scherer, unpublished) Neurologic symptoms. [152] ur. and
bowel inc. [156]
[152]
L106P Spasticity, ur. inc. [156]
L113P Spastic paraparesis. [157] UMN, MRI
WMC and low signal in gray matter
c/w iron deposition.[153]
[157,211,228] originally in [153]
(continued on next page)
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Table 2 (continued).
Mutation Functional assay (transfected cell lines unless
noted)
Localization in mammalian cells (transfected
cell lines unless noted)
Neurologic phenotype References
Others note no neurologic ﬁndings
[228]
I130T Markedly decreased coupling; single channel size
normal. [189,191]
No dye transfer by scrape load or hemichannel
activity by dye uptake. [188]
GJ-like plaques. [191]
GJ-like plaques (very reduced). [189]
GJ-like plaques (slightly reduced). [188]
Spastic para- or tetraparesis; epilepsy,
ur. Inc. MRI cerebellum/midbrain
atrophy or hypoplasia [167]
[152,167]
K134E Markedly decreased or absent coupling; reduced
single channel size (54 pS) [191] Reduced coupling.
[189]
GJ-like plaques. [191]
GJ-like plaques (very reduced). [189]
“Neurologic symptoms.” [152] UMN,
MRI WMC. [156]
[152]
K134N Reduced coupling.[189] GJ-like plaques (very reduced). [189] UMN. [156] [211] probably described previously[229]
G138R No homotypic, coupling, shifted Gj–Vj relation in
hetrotypic with Cx43-EGFP. Increased hemichannel
activity no neurobiotin transfer[193] [187] No
homotypic coupling. [190,191] Dominant negative
effect on endogenous Cx43 in NRK cells [190] and
Hela and N2a cells. [223]
GJ-like plaques. [191]
GJ-like plaques and cytopasmic. [187]
4 generations 1 and 2: no neurologic
ﬁndings. 3 and 4: spastic bladder
paraparesis, square wave jerks and
intention tremor presented 2nd to
4th decade. documented WMC on
MRI [168] UMN, ur. inc., MRI WMC.
[156]
[152] originally described in [168,206]
T154A Mild psychomotor delay andWMC on
MRI scan. [230] Gait abnl, UMN, ur.
inc., MRI WMC. [156]
[156,230]
T154N Spastic paraparesis, inc., tremor. [157] [157]
V216L Decreased coupling in patient ﬁbroblasts. [169]
No conductance and dominant negative effect on
endogenous Cx43 mediated NRK coupling. [185]
Partial overlap with Golgi marker (but also some
WT in Golgi distribution) in patient ﬁbroblasts.
[169]
Few GJ-like plaques partial intracellular
retention [185] GJ-like plaques. (S. Scherer,
unpublished)
Spasticity, WMC on MRI.[172]
Gastrointestinal hypomotility,
neurogenic bladder, lost ambulation
at age 54; hyperreﬂexia, spasticity.
[169]
UMN, MRI WMC ur. and bowel inc.
[156]
[152,169] originally described in [172,206]
S220Y Developmental and language
disorder. [157]
[157]
No identiﬁed mutation
? Spasticity. [158]
? Severe spasticity. [159]
? Spastic tetraparesis. [160]
? Spastic paraparesis, nystagmus. [161]
? Spastic paraparesis and decreased
signal c/w iron deposition in globus
pallidus on MRI.
[231]
? 21 YO F spastic paraparesis MRI WMC
and low signal in gray matter c/w iron
deposition.
[164]
? MRI diffuse WMC, Abnl low signal in
globus pallidus, substantia nigra
without calciﬁcation on CT c/w iron
deposition. (Fig. 2B).
[165]
WMC—whitematter changes, typically increase signal on T2weighted imaging. c/w— consistentwith. GJ— gap junction. YO— years old. abnl— abnormal. nl—normal. h/o—history of. Gj-Vj— normalized conductance-voltage relation. UMN—
upper motor neuron (spasticity/hyperreﬂexia). ur inc — urinary incontinence. neuro — neurological.
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The genetics of ODDD and HSS indicate that ODDD is not the result
of haploinsufﬁciency. The heterozygous parents of patients with the
R33X [180] and R76S [179] mutations were normal. The mother of the
severely affected girl with a compound G2 frameshift and R101X
mutations (both of which would likely cause loss of function) was
heterozygous for the R101X mutation, and said to have “mild
microphthalmia and hypoplastic alae nasi” [173], although those
features are difﬁcult to appreciate in the image provided. In accord,
heterozygous Gja1 knockout mice show no overt phenotype in any
organ system [184], whereas mice with dominant Gja1 mutations
have phenotypes that resemble those in ODDD (see below).
Many ODDD mutants have been expressed by transfection in
heterologous cells (Table 2). These results bring up the following
points:
1. Irrespective of known CNS involvement, most, but not all, ODDD
mutants studied can form GJ plaques [169,185–191]. (The number
may be reduced for some mutants.) Thus, there is no apparent
association between the targeting of the Cx43 mutant to gap
junctions and the presence of a CNS phenotype.
2. Functional analyses show that ODDD mutants lead to partial or
complete loss of intercellular GJ mediated coupling, andmany have
dominant-negative effects onwild typeCx43 [185,188–190,192]. The
degree of this dominant-negative effect varies, but it remains to be
determined whether this correlates with the severity of disease,
including the presence of CNSmanifestations. For example, L90V and
V216L (“CNS mutants”) and R202H (a “non-CNS mutant”) reduce
Cx43-mediated cell coupling to a similar degree [185]. In addition, it
is possible that “trans-dominant-negative” effects of Cx43 mutants
on Cx30 (or possibly Cx26) contribute to their clinical phenotypes.
3. Several mutants affect hemichannel properties: Y17S, G21R, A40V,
F52dup, L90V and 1130T all lack hemichannel function, I131M,
G138R, G143S all show increased hemichannel activity, while the
hemichannel activity of H94P is similar to that ofWT [188,193]. It is
possible, but by no means proven, that hemi-channel activity
contributes to the ODDD phenotype.
4. I131M, G138R, G143S, and H194P have reduced phosphorylation, a
post-translational modiﬁcation of Cx43 that is associated with
increased coupling [194]. Because some (G138R and H194P) but
not all (I131M and G143S) of these mutants are associated with
neurological ﬁndings, the role of phosphorylated Cx43 in this
regard remains unproved.
5. The accumulation of Cx43 mutants in intracellular organelles may
have deleterious effects on the cells, possibly by activating the UPR
as discussed for PMLD1 in Section 4.3 [147–149].
6. Reduced Cx43 in GJ plaques may have deleterious effects on
localization of other proteins with which it normally interacts, as
outlined in Section 2.2.2.
There are several mouse models of ODDD. Jrt mice are heterozy-
gous for a dominant G60S mutation, and showmany of the features of
ODDD but have no overt CNS ﬁndings or brain MRI abnormalities at
52–60 weeks [195]. Immunohistochemistry and immunoblotting of
spinal cord and cerebellum from Jrt mice show decreased staining and
decreased levels of Cx43, but astrocytes were still well coupled by GJs,
both in vitro and in vivo [196]. In transfected cells, G60S formed GJs
that did not pass Lucifer Yellow, but a dominant-negative effect on
wild type Cx43 could not be demonstrated [196]. Heterozygous mice
with a targeted replacement of WT Cx43 by the ODDD I130T [197] or
G138R [193] mutations have reduced embryonic viability, cardiac
dysrhythmias, and reduced Cx43 levels in heart tissue, but the CNS
was not investigated. Because none of the ﬁndings seen in the mouse
models have been reported in heterozygous Gja1 knockout mice
[184], they are dominant effects.In summary, the analysis of cellular and mouse models of ODDD
demonstrates that ODDD mutants have several kinds of dominant
effects. Of these, dominant-negative effects on wild type Cx43 are by
far the best documented, but it remains to be shown that they are
sufﬁcient to account for all of the various attributes of ODDD. The
striking phenotypic similarities between patients with ODDD
(cause by gain of function mutations) and HSS (caused by loss of
function mutations) make a dominant-negative mechanism the most
parsimonious explanation.
6. Conclusion
There are ﬁve CNS disorders associated with mutations in three
connexin genes. Two disorders, PMLD1 and SPG44, are deﬁned by
their CNS manifestations and are associated with recessive GJC2
mutations. Available evidence suggests loss of function of Cx47 is at
least partially responsible for these disorders. The difference in
severity between the patients with PMLD1 and SPG44 is not well
understood, but may reﬂect either lesser degrees of loss of function for
the mutation causing the milder SPG44 phenotype or a component of
gain of function for the mutations causing the more severe PMLD1
phenotype. GJB1mutations cause CMT1X, which alwaysmanifests as a
peripheral neuropathy, are often associated with subclinical neuro-
logical ﬁndings, and are rarely associated with a severe but transient
syndrome. Though the neuropathy appears related primarily to loss of
function of Cx32 in the Schwann cell, CNS manifestations are more
likely due to a toxic gain of function in oligodendrocytes. Dominant
GJA1 mutations cause ODDD, which is often associated with a CNS
phenotype, and recessive GJA1 mutations cause HSS, which strongly
resembles ODDD. The genetics of HSS demonstrate that haploinsufﬁ-
ciency cannot explain the ODDD phenotype. However, a dominant
negative effect on wild-type Cx43 has been demonstrated for a number
of ODDD mutants; it remains to be demonstrated that such effects
explain the full range of phenotypic manifestations of this disorder.
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